Fig. 2: Vaccine-induced EBOV GP-binding antibody concentrations.

a, Anti-EBOV GP-specific binding antibody concentrations in vaccinated women over time. GMCs with 95% CI are shown in the figure. Group A, pregnant women randomized to be vaccinated during pregnancy; group B, pregnant women randomized to be vaccinated after pregnancy. Enrollment of first-trimester pregnant women was opened after the immunogenicity subset was fully enrolled. As a result, no first-trimester pregnant women were included in the immunogenicity subset. b, Correlation between mother anti-EBOV GP-specific binding antibody concentration at postpartum day 1 and mother cord blood anti-EBOV GP-specific binding antibody concentration at postpartum day 1. c, Correlation between mother anti-EBOV GP-specific binding antibody concentration at postpartum day 1 versus infant anti-EBOV GP-specific binding antibody concentration at 14 weeks of age. d, Correlation between mother cord blood anti-EBOV GP-specific binding antibody concentration at postpartum day 1 versus infant anti-EBOV GP-specific binding antibody concentration at 14 weeks of age. For b–d, the Spearman correlation coefficients calculated are partial Spearman correlation coefficients that control for the trimester of the mother at randomization. For a–d, trimester refers to the trimester at randomization. First trimester, 0–12 weeks; second trimester, >12–24 weeks; third trimester, >24 weeks. EU, enzyme-linked immunosorbent assay units. N/A, not applicable.